Stellate Ganglion Block for Anosmia and Dysgeusia Due to Long COVID

Gaurav Chauhan, Aman Upadhyay, Suchit Khanduja, Trent Emerick, Gaurav Chauhan, Aman Upadhyay, Suchit Khanduja, Trent Emerick

Abstract

Anosmia and parosmia refer to the loss or dysfunction of smell, respectively. Dysgeusia refers to taste disturbance. The coronavirus disease 2019 (COVID-19) pandemic and the subsequent phenomenon of Long COVID syndrome have been associated with an increased incidence of anosmia and dysgeusia. Smell and taste disturbances associated with COVID-19 are usually self-limiting but can persist for longer periods in some cases. Imbalances of the autonomic nervous system, especially dysregulation of the sympathetic system, are implicated in the persistence of anosmia and dysgeusia post-COVID-19 infection. Stellate ganglion block (SGB) can diminish the increased sympathetic activity and potentially resolve anosmia and dysgeusia occurring due to Long COVID. The authors report the successful resolution of persistent anosmia and dysgeusia due to Long COVID in a female patient after she underwent SGB.

Keywords: anosmia; covid-19; dysautonomia; dysgeusia; long-covid.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2022, Chauhan et al.

Figures

Figure 1. Ultrasonographic image of the right…
Figure 1. Ultrasonographic image of the right side of the neck depicting stellate ganglion
a: stellate ganglion above the longus colli muscle. Site for deposition of local anesthetic solution. b: longus colli muscle. c: right carotid artery

References

    1. COVID-19 and anosmia: a review based on up-to-date knowledge. Meng X, Deng Y, Dai Z, Meng Z. Am J Otolaryngol. 2020;41:102581.
    1. COVID-19 related olfactory dysfunction. Karamali K, Elliott M, Hopkins C. Curr Opin Otolaryngol Head Neck Surg. 2022;30:19–25.
    1. The temporal course of COVID-19 anosmia and relation to other clinical symptoms. Altundag A, Saatci O, Sanli DE, et al. Eur Arch Otorhinolaryngol. 2021;278:1891–1897.
    1. Dysautonomia and implications for anosmia in long COVID-19 disease. Vallée A. J Clin Med. 2021;10:1–5.
    1. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Zayet S, Kadiane-Oussou NJ, Lepiller Q, et al. Microbes Infect. 2020;22:481–488.
    1. Dysautonomia: an overlooked neurological manifestation in a critically ill COVID-19 patient. Eshak N, Abdelnabi M, Ball S, Elgwairi E, Creed K, Test V, Nugent K. Am J Med Sci. 2020;360:427–429.
    1. COVID-19 is getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from SARS-CoV-2. Stute NL, Stickford JL, Province VM, Augenreich MA, Ratchford SM, Stickford AS. J Physiol. 2021;599:4269–4285.
    1. Morphological spectra of adult human stellate ganglia: implications for thoracic sympathetic denervation. Kwon OJ, Pendekanti S, Fox JN, et al. Anat Rec (Hoboken) 2018;301:1244–1250.
    1. Stellate ganglion block reduces symptoms of Long COVID: a case series. Liu LD, Duricka DL. J Neuroimmunol. 2022;362:577784.
    1. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Mil Med. 2014;179:1133–1140.
    1. Effective use of percutaneous stellate ganglion blockade in patients with electrical storm. Tian Y, Wittwer ED, Kapa S, et al. Circ Arrhythm Electrophysiol. 2019;12:0.
    1. Comparison of the effects of stellate ganglion block and paroxetine on hot flashes and sleep disturbance in breast cancer survivors. Rahimzadeh P, Imani F, Nafissi N, Ebrahimi B, Faiz SH. Cancer Manag Res. 2018;10:4831–4837.
    1. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. Vaira LA, Hopkins C, Sandison A, et al. J Laryngol Otol. 2020;134:1123–1127.
    1. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Brann DH, Tsukahara T, Weinreb C, et al. Sci Adv. 2020;6:1–5.
    1. Clinical characterization of dysautonomia in long COVID-19 patients. Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Sci Rep. 2021;11:14042.
    1. The cellular basis of loss of smell in 2019-nCoV-infected individuals. Gupta K, Mohanty SK, Mittal A, et al. Brief Bioinform. 2021;22:873–881.
    1. Proinflammatory actions of angiotensins. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Rupérez M, Egido J. Curr Opin Nephrol Hypertens. 2001;10:321–329.
    1. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Verma S, Abbas M, Verma S, et al. Infect Genet Evol. 2021;91:104801.
    1. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review: high levels of anti-SSA/Ro antibodies in COVID-19. Fujii H, Tsuji T, Yuba T, et al. Clin Rheumatol. 2020;39:3171–3175.
    1. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. Zhang Y, Cao W, Jiang W, et al. J Thromb Thrombolysis. 2020;50:580–586.
    1. Diverse functional autoantibodies in patients with COVID-19. Wang EY, Mao T, Klein J, et al. Nature. 2021;595:283–288.
    1. COVID-19: possible reasons for the increased prevalence of olfactory and gustatory dysfunction observed in European studies. Gourtsoyannis Y. Clin Infect Dis. 2020;71:0.
    1. Age-dependent sensory impairment in COVID-19 infection and its correlation with ACE2 expression. Somekh I, Yakub Hanna H, Heller E, Bibi H, Somekh E. Pediatr Infect Dis J. 2020;39:0–2.
    1. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Eur Arch Otorhinolaryngol. 2020;277:2251–2261.
    1. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, Lim PB. Clin Med (Lond) 2021;21:0–7.
    1. Cerebral blood flow remains reduced after tilt testing in myalgic encephalomyelitis/chronic fatigue syndrome patients. van Campen CL, Rowe PC, Visser FC. Clin Neurophysiol Pract. 2021;6:245–255.
    1. Sympathetic regulation of cerebral blood flow in humans: a review. ter Laan M, van Dijk JM, Elting JW, Staal MJ, Absalom AR. Br J Anaesth. 2013;111:361–367.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel